Browsing by Author "Meena Kumari"

Now showing 1 - 2 of 2

An approach to the understanding of the clinical-etiopathological aspect of COVID-19 (SARS-CoV-2)
(J. K. Welfare and Pharmascope Foundation, 2020) Meena Kumari; Monika Agrawal; Rakesh Kumar Singh; Parameswarappa S. Byadgi
Currently, the world is facing a health and socioeconomic crisis caused by the novel coronavirus disease COVID-19. On 11 March 2020, the World Health Organization (WHO) has declared this disease as a pandemic. The condition (COVID-19) is an infectious disorder triggered by a newly discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2. Most of the COVID-19 infected patients will experience mild to moderate respiratory symptoms and recover without any unique therapy. Assessment of the clinical and epidemio-logical characteristics of SARS-CoV-2 cases suggests the infected patients will not be contagious until the onset of severe symptoms and affects the other organs. Well-differentiated cells of apical airway epithelia communicating with ACE2 were promptly infected to SARS-CoV-2 virus. But the expression of ACE 2 in poorly differentiated epithelia facilitated SARS spike (S) protein-pseudo typed virus entry and it is replicated in polarized epithelia and espe-cially exited via the apical surface. Limiting the transmission of COVID-19 infection & its prevention can be regarded as a hierarchy of controls. In this article, we briefly discuss the most recent advances in respect to aetiology, pathogenesis and clinical progression of the disease COVID-19. © 2020, J. K. Welfare and Pharmascope Foundation. All rights reserved.
Clinical efficacy of Gojihvadi Kwath, Shirishadi Kwath, Sanjeevani Vati, Panchagavya Ghrita Granules & Shunthi Churna for COVID-19 management, a randomized controlled trial
(National Institute of Science Communication and Policy Research, 2024) Parameswarappa S. Byadgi; Meena Kumari; Vishwambhar Singh; Arun Kumar Dwivedi; Sunil Kumar Mishra; Sushil Kumar Dubey; Ashvanee Kumar Chaudhary; R.N. Chaurasia; Namrata Joshi; Hitesh Jani; Rajeev Kumar Mishra; T.B. Singh; P.S. Arunima; Remya Jayakumar
The obscure disease pattern of COVID-19 have to be evaluated with Ayurvedic interventions and the present clinical trial was a randomized open label parallel three-arm control trial on the major and minor symptomatic patients with the recent pandemic. The patients were recruited from the Super specialty building of Sir Sunderlal hospital, COVID-19 ward and home isolated ones. The Ayurvedic intervention includes the 15 days oral administration (Group A) –Gojihvadi Kwath, Sanjeevani Vati; Panchagavya Ghrit Granules; Shunthi (Dry ginger powder) plus conventional treatment, in (Group B) – Shirishadi Kwath, Sanjeevani Vati; Panchagavya Ghrit Granules; Shunthi (Dry ginger powder) plus conventional treatment and in Group C (control group) only the conventional medicines. Assessment was done based on the RT-PCR reports, signs and symptoms. The results point out the efficacy of trial medicine (that is group A and B) to discharge the patients earlier than those from the control group. The early reduction in the signs and symptoms noted were also observed. Group B showed a faster recovery from dry cough and shortness of breath and improvement in appetite. Home-isolation patients showed faster recovery of clinical symptoms than the hospitalized patients. Ayurvedic interventions can accelerate viral load clearance associated with quicker recovery and concurrently decrease the risk of viral dissemination. Additionally, there were no adverse reactions observed with these trial medicines. © 2024, National Institute of Science Communication and Policy Research. All rights reserved.